Back

Galectin-3 predicts the risk of ventricular tachycardia in ischemic heart failure patients with implantable cardioverter-defibrillator

29 June 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Chronic Heart Failure - Pathophysiology and Mechanisms 2 Systolic Ventricular Dysfunction HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Elena Grakova

Cardiology Research Institute, Tomsk National Research Medical Centre of Russian Academy of Science, Tomsk (Russian Federation)

9 More presentations in this session

Presentation thumbnail
Blood pressure response and safety outcomes with vericiguat in the VICTORIA trial
Doctor C. Lam (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Long-term outcomes in heart failure with preserved ejection fraction: predictors of cardiovascular and non-cardiovascular mortality
Ms A. Shahim (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
The impact of multimorbidity on mortality in heart failure with reduced ejection fraction (HFrEF): Which comorbidities matter most?
Doctor P. Dewan (London, GB)
Abstract Slides Video
Presentation thumbnail
Acute changes in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF
Doctor K. Docherty (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Clinical outcome predictions for the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial
Doctor R. Mentz (Durham, US)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic Heart Failure - Pathophysiology and Mechanisms 2

The Event

Event poster

Heart Failure 2021

29 June - 1 July 2021
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on vascular (dys)function in the failing heart
thumbnail
Congress Session
Heart failure in the era of precision medicine: insights into pathophysiology and emerging treatments
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources